AT
private_company

Allogene Therapeutics

Allogene Therapeutics is an investor based in Canada, investing in Healthcare & Life Sciences, Medical Device and Biotech, 1 tracked investment.

1
Investments Tracked

About Allogene Therapeutics

Allogene Therapeutics is an investor based in Canada. Brouky tracks 1 investment associated with the firm.

Allogene Therapeutics invests across Healthcare & Life Sciences, Medical Device, Biotech and Digital Health. Coverage extends to 6 sectors in total. Investments are concentrated at Series A.

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. They are focused on delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

Investment Focus

Stage Focus
series-a
Sectors
Healthcare & Life Sciencesmedical-devicebiotechdigital-healthhealthcarer-d

Investment Thesis

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. They are focused on delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients.

Team

Arie BelldegrunExecutive Chairman and Co-Founder

Arie Belldegrun, M.D., is the Executive Chairman and Co-Founder of Allogene. He currently serves as Chairman of Two River Group, UroGen Pharma, Kronos Bio, and as Co-Chairman of Breakthrough Properties.

David ChangPresident, Chief Executive Officer and Co-Founder

David Chang, M.D., Ph.D, is the President, Chief Executive Officer and Co-Founder of Allogene Therapeutics.

Benjamin M. BeneskiSenior Vice President, Chief Technical Officer

Ben Beneski is the Senior Vice President and Chief Technical Officer of Allogene.

Christine CassianoExecutive Vice President, Chief Corporate Affairs and Brand Strategy Officer
Earl DouglasGeneral Counsel
Susie LundeenChief People Officer
Geoffrey ParkerExecutive Vice President, Chief Financial Officer
Zachary J. RobertsExecutive Vice President, Research & Development, Chief Medical Officer
Liz BarrettPresident and Chief Executive Officer of UroGen, Former CEO of Novartis Oncology
John DeYoungVice President, Worldwide Business Development, Pfizer
Franz B. HumerLead Independent Director of Allogene, Former Chairman and Chief Executive Officer, Roche Holding Ltd.
Joshua KazamCo-Founder and Partner of Two River, Co-Founder and Director of Vida Ventures, Co-Founder of Allogene

Explore Allogene Therapeutics's full profile on Brouky

Portfolio companies, co-investors, AI match scores, and deal flow signals.

Other Investors in Canada

Other Investors in Healthcare & Life Sciences / Medical Device